S100A8 and Crohn disease: For example, in the treatment of femoral head osteoarthritis, it reduces serum levels of S100A9 protein, thus contributing to improved tissue vascularisation [80,81], while in Crohn’s disease, it has a down-regulating effect on S100A8/S100A9 heterotetramers (calprotectin) [82].